Patients’ quality of life during active cancer treatment: a qualitative study

Jordan Sibeoni1,2*, Camille Picard3,4, Massimiliano Orrì2,5, Mathilde Labey2,6, Guilhem Bousquet7,8, Laurence Verneuil2 and Anne Revah-Levy1,2

Abstract

Background: Patients’ quality of life has become a major objective of care in oncology. At the same time, it has become the object of increasing interest by researchers, working with both quantitative and qualitative methods. Progress in oncology has enabled more patients to survive longer, so that cancer is increasingly often a chronic disease that requires long-term treatment that can have negative effects on patients’ quality of daily life. Nonetheless, no qualitative study has explored what patients report affects their quality of daily life during the treatment period. This study is intended to fill this gap.

Methods: We conducted a multicenter qualitative study based on 30 semi-structured interviews. Participants, purposively selected until data saturation, had diverse types of cancer and had started treatment at least 6 months before interview. Data were examined by thematic analysis.

Results: Our analysis found two themes: (1) what negatively affected for patient’s quality of daily life during the treatment period, a question to which patients responded by talking only about the side effects of treatment; and (2) what positively affected their quality of daily life during the treatment period with three sub-themes: (i) The interest in having — investing in — a support object that can be defined as an object, a relationship or an activity particularly invested by the patients which makes them feel good and makes the cancer and its treatment bearable, (ii) The subjective perception of the efficacy of the antitumor treatment and (iii) the positive effects of relationships, with friends and family, and also with their physician.

Conclusions: Patients must be involved in their care if they are to be able to bear their course of treatment and find ways to endure the difficult experience of cancer care. The support object represents an important therapeutic lever that can be used by their oncologists. They should be interested in their support objects, in order to support the patients in this investment and to help them to maintain it throughout the health care pathway. Furthermore, showing interest in this topic, important to the patient, could improve the physician-patient relation without using up very much of the physician’s time.

Keywords: Qualitative research, Oncology, Care, Physician-patient relationship, Quality of life
Background
In the field of oncology, medical advances and the development of evidence-based medicine (EBM) have produced major progress in terms of both survival and quality of care. At the same time, patients’ quality of life (QoL) has become a major objective of cancer care, considered by some authors to be the leading patient-reported outcomes for all treatment in this field [1].

There is accordingly a substantial literature on QoL and the health-related QoL of patients with cancer. It has primarily focused on:

- the impact on QoL of specific types of cancer [2–4]; or a specific treatment by surgery, radiation therapy, chemotherapy, or hormonal therapy [5–7];
- psychosocial interventions aimed at improving the QoL of cancer patients [8, 9];
- factors associated with QoL in cancer patients: anxiety and depression [10], coping strategies [11], physical exercise [12], and finances [13].

QoL in oncology is explored principally among two populations of patients: those with cancer at an advanced stage or in palliative care [14, 15] and survivors of specific types of cancers [16, 17].

Moreover, in these studies, the term QoL is understood as the results of quantitative measures to assess levels of wellness of the patient are the quality of life, that is to quantify the impact of a cancer using a psychometric approach and several concepts such as for instance physical functioning, role-physical, bodily pain, general health perceptions, vitality, social functioning, role-emotional, and mental health [18].

Exploring the quality of life of patients with cancer also requires to take an interest in their daily lives and to focus directly on their views. That requires to consider quality of life otherwise, based on the subjective experience of the patients’ day-to-day lives, what we chose to name quality of daily life.

Qualitative methods are useful in this context, aiming as they do to describe and understand complex phenomena in greater depth [19]. They are a tool of choice for focusing on the views of patients directly in their context. Yet, qualitative methods are rarely used among patients with cancer to address the views of cancer patients about their quality of daily life, again principally among survivors or those in advanced-stage or palliative situations [20, 21].

To our knowledge, no study has ever explored how cancer patients experience their quality of daily life during the treatment period. Their increased survival due to advances in oncology has led to longer, chronic disease and requires them to be in treatment for longer periods, with an accompanying risk of impaired quality of life on a daily basis and long-term physical and psychological effects during this period [22]. This phase of curative treatment, before the questions of survival and of palliative care arise, also affects patients’ quality of daily life.

Based on an exploration of the daily life of patients during the active treatment period, this qualitative study aimed to explore what affected their quality of daily life, either during the treatment or in their daily life.

Methods
This exploratory national multicenter study involved oncology departments at three university hospitals, two located in the Paris area (Saint-Louis Hospital, Paris, and Avicenne Hospital, Bobigny), and one in northern France (Caen). The study design is detailed in Table 1. We used a qualitative methodology: sampling was purposive [23], data were collected from individual interviews, and data saturation was achieved according to the principle of theoretical sufficiency [24]. The analysis, aided by Nvivo 11 software, used a thematic approach [25], Table 2 summarizes the different stages of our thematic analysis. This study complies with the SRQR guideline [26].

In the results that follow, extracts of the transcripts have been selected to exemplify the themes described. All personal information has been removed, to protect the confidentiality of the participants. The verbatim account has been freely translated into English for the sole purposes of this article.

Results
We included 30 patients. All of the patients asked for interviews agreed to participate. Table 3 presents their social and clinical characteristics. Our sample was 57% female (M = 13, F = 17) and had a mean age of 63.5 years - from 31 to 77 years old-. The median time since diagnosis was 4 years, and all patients had undergone several different treatments.

The presentation of our results is structured by two themes: (1) what negatively affected for their quality of daily life during the treatment period, a question to which patients responded by talking only about the side effects of treatment; and (2) what positively affected their quality of daily life during the treatment period: use of a support object/activity during the treatment period, antitumor treatment, and relationships.

What negatively affected for quality of daily life:
Treatment side effects
The adverse effects of antitumor treatments
The patients included in our study found the adverse effects of antitumor treatments difficult to live with. First, they dreaded these effects, especially those due to chemotherapy.
P3: “It’s true that I was very afraid of chemotherapy. I said to myself that everyone who has chemo, they are very sick. They vomit. I told myself, I’m going to lose my hair, I’m going to lose weight, I’m going to vomit. I’m not going to eat.”

P4: “All that I knew about chemo was from movies in the 1980s where people were as sick as dogs all the time for weeks.”

Then they complained about the side effects, such as nausea and vomiting or asthenia, which strongly affected their day-to-day quality of life. They also reported that they were unable to accomplish the tasks of daily living or to do any leisure activities.

P10: “I could never go back to the work I did before, I wouldn’t have the energy.”

P12: “Chemo is so powerful and so noxious at the same time that really, what a bitch when you see the side effects. I couldn’t do my errands, couldn’t go shopping or to the movies for months.”
Finally, they lamented the persistent sensory effects, such as the loss of a sense of taste, and those that impaired their self-image, such as the loss of hair, mentioned as often by men as by women.

P17: “I had chemo, hard chemo. It made my hair fall out, it destroyed everything it went through. If you talk about the effects of chemo, it’s the hair, and then the nails, and gastrointestinal problems.”

The paradoxical experience of adverse effects
We also found a paradoxical experience around these side effects. Simultaneously, chemotherapy made them feel bad and had numerous burdensome effects, but these also became an indicator of its therapeutic efficacy.

P20: “It destroys the diseased cells, with an impact that we call side effects, collateral damage.”

P29: “What matters is the result. We know that chemo kills good cells, but it also kills the bad ones.”

Similarly, we observed patients’ ambivalence toward invasive treatment such as surgery, experienced as burdensome and dangerous but also as radical and more effective.

P23: “I had a rotten bladder, they took it out, but the party goes on, if I can say it like that.”

P28: “The lung operation was hard to stand, you don’t recover just like that, but then, afterwards, it went better.”

What positively affects the quality of daily life
Patients’ narratives about what allowed them to maintain a good quality of daily life on a daily basis during treatment were richer and more varied. They emphasized three different aspects:

– (i) The interest in having —investing in — a support object. We have chosen to translate the French idiom “objet d’étayage” by the English term Support object. “Objet d’étayage/support object can be defined as an object, a relationship or an activity particularly invested by the patients in their daily lives, which makes them feel good and makes the cancer and its treatment bearable.

– (ii) Their subjective perception of the efficacy of the antitumor treatment also exerted a positive impact on their quality of daily life.

– (iii) The positive effects of relationships.

The support object
Most of the patients had an activity or relationship especially important to them that was good for them and helped them to live better with their disease and its treatment. This real function of this object was to support them.

P1: “My camping car. That’s what saved me. I love to travel! Roaming, I love it.”

For some patients, this was a regular physical activity. They described a physical effect, that is, an awareness of their physical capacity. They also mentioned a moment of escape, where they were not thinking about their disease and, for those who did team sports, the
ability to maintain a social association outside of a health context.

P27: “I began to play golf too: to let go and not think about anything. And that, it was really good. It’s always really good, it lets you think only about yourself, already, a little, and to escape from all that. It lets you really concentrate, to empty your head and not think about anything but yourself.”

For other patients, it was a hobby or traveling, again something that let them take themselves out of the everyday and escape from the disease and from treatment.

P10: “What helped me most was all the beautiful performances I saw, which are still like a small fire inside me.”

For others, it could be work, or religious or spiritual practice, or meditation.

P7: “I’m a deputy mayor in my municipality; [the cancer] doesn’t keep me from going to spend two hours a day at city hall and participating in town council meetings. I live normally.”

P30: “Yoga with its Hindu philosophy, it really puts things in perspective.”

Subjective perception of the effectiveness of antitumor treatment

What positively affected patients’ quality of daily life, according to them, was perceiving that their antitumor treatment was effective. They had a representation of cancer treatment as a battle against the disease; treatment was perceived as effective if it halted the disease and ineffective if it did not.

P11: “Chemo, that helped me. Stopped the bad stuff.”

P7: “I cannot say that the treatment is helpful today, because I have more lesions today than I did two months ago.”

Some patients relied on and appropriated clinical or paraclinical efficacy criteria, such as tumor size on imaging or the lab measurements of tumor markers.

P2: “When the PSA goes down, I’m in a better mood, it makes me happy.”

The type of treatment also influenced the perception of efficacy. Patients found it easier to perceive surgical treatment as effective. Patients described surgery as a one-time procedure with generally a curative objective: total ablation of the tumor.

P18: “As soon as they told us the day after the operation that it had succeeded, all we had to do was wait to get better. Finally it wasn’t so awful.”

Inversely, patients perceived the unavailability of surgical treatment as inefficacy.

P5: “But they didn’t operate on me. Because otherwise, I said, take off both breasts and we’re done. But apparently it wasn’t possible, it was inoperable.”

---

**Table 3** Summary of participants

| Category                                      | n (%) |
|----------------------------------------------|-------|
| Gender, women                                | 17 (57) |
| Age, mean y                                  | 63.5 |
| 30–40                                        | 3 (10) |
| 40–50                                        | 5 (17) |
| 50–60                                        | 6 (20) |
| 60–70                                        | 9 (30) |
| ≥ 70                                         | 7 (23) |
| Cancer type                                  |       |
| Breast carcinoma                             | 9 (30) |
| Lung carcinoma                               | 1 (3) |
| Melanoma                                     | 7 (23) |
| Skin lymphoma                                | 6 (20) |
| Bladder/kidney carcinoma                     | 3 (10) |
| Prostate carcinoma                           | 1 (3) |
| Testis germ cell cancer                      | 1 (3) |
| Ovaries                                      | 2 (7) |
| Disease stage                                |       |
| Metastatic                                   | 14 (47) |
| Localized                                    | 16 (53) |
| Treatment received                           |       |
| Intravenous chemotherapy only                | 6 (20) |
| Intravenous chemotherapy + others            | 19 (63) |
| Oral chemotherapy, other treatments          | 5 (17) |
| Duration of cancer treatment period          |       |
| Less than 1 year                             | 6 (20) |
| 1 to 3 years                                 | 6 (20) |
| 3 to 5 years                                 | 12 (40) |
| More than 5 years                            | 6 (20) |
| Recruitment site                             |       |
| Paris St Louis Hospital                      | 15 (50) |
| Bobigny, Avicenne Hospital                   | 3 (10) |
| Caen, university hospital centre             | 12 (40) |
Relationships

Relationships had an important place in patients' discourse.

The presence of family and close friends was very important for the patients, so that they were not alone and so that they had support during treatment, and also in their daily life.

P3: “What's sure is I had my friend. He came each time I had chemo. He was with me. It's true that, if I had been all alone, at home, it would have been harder. He helped me.”

The relationship with the physician was also very important. What was helpful, according to the patients, was the establishment of a trusting relationship with the physician together with the latter's involvement and availability.

P10: “I know that he is someone who is very committed, very involved, who won't let me down.”

Patients were also very sensitive to the physician's ability to listen and to reassure.

P17: “And it's also the difference between a good and a bad doctor, because behind that it means he's listening.”

The quality of the relationship appeared more important than the time spent with the patient or the information provided.

P18: “I never need to spend very long with a doctor; finally, I often go right to the essential part. We all know that we're not the only person they are taking care of, but, no, I never had the impression I'm being rushed.”

The patients also reported positive effects of a convivial and sympathetic treatment environment, directly associated with their relationship with the health care team and especially the nurses.

P17: “Support from the nurses has always been great. I don't know how they do it, but they manage to say something nice to everyone. To show their interest, and even to remember people.”

Finally, relationships with the other patients were also experienced as helpful, when it provided hope, mutual assistance, and friendliness.

P4: “She told me she had had a remission for 18 years. But suddenly, there was hope. If she could have 18 years, I can too.”

Discussion

Our results are structured around the dialectic with, on the one hand, what negatively affected quality of daily life, which for all patients was always only the side effects of treatment, and on the other hand, what had a positive effect on quality of daily life, including a support object or activity, the perceived efficacy of the treatment, and relationships.

The only topic covered in the patient's narratives of things that negatively affected their quality of daily life was side effects, which recurred over and over, invading their discourse throughout the interviews. Both the ubiquity and the invasiveness of side effects in the patients' experience lead us to discuss two specific points: the potentially post-traumatic dimension of this experience of side effects and the importance of daily life for the patients.

Several studies have found a relatively substantial frequency of post-traumatic symptoms, and even of full post-traumatic stress disorder (PTSD) in patients with cancer [27]. PTSD is a mental health condition triggered by a traumatic event, either experienced or witnessed. Symptoms include intrusive memories (flashbacks) and uncontrollable thoughts about the event, nightmares, avoidance reactions, severe anxiety, negative mood and emotional reactions. PTSD cause significant social distress and can lead to other psychiatric issues such as depression [28]. A meta-analysis found a lifetime prevalence of cancer-related PTSD of 12.6% [29]. The adverse effects of antitumor treatment are reported to be a potentially determinant factor of these symptoms but are not considered as a separate experience in the patient's history. Our results suggest, nonetheless, that the experience of the side effects of antitumor treatment in these patients could have a specific post-traumatic dimension, and could be considered as a traumatic stressor [30], that may thus require targeted screening, evaluation, and interventions.

There is a substantial literature describing the influence of these side effects on treatment decisions [31] as well as, especially, their negative impact on patients' QoL. [32–34]. Prolonging treatment and focusing only on survival, does not meet all patients' needs [35]. In our results, the patients underlined the importance of living with cancer on a day-to-day basis, that is, not only living as long as possible, but also as well as possible in their everyday life. The importance of interpersonal relationships and of the quality of the physician-patient relationship has been known and reported repeatedly in the literature [36, 37]. Our results describe an original aspect of what directly and positively affects patients' quality of daily life: involvement
with a support object. The support object, in our opinion, represents an important therapeutic lever that can be used to improve the physician-patient relationship. That is, when patients are able to choose and be involved with a support object or activity, the physician must support them and converse with them on this topic.

Clinical implications
Numerous studies have showed that physicians fail to take the spiritual and religious concerns of their severely ill patients into account [38], despite the demonstrated benefits in terms of patients’ satisfaction and the importance of these aspects to their QoL [39]. In the field of cancer care, physicians should be interested in their patients’ support objects, whatever they are. First, this allows doctors to support the patients in their investment in this object and to help them maintain this investment throughout the health care pathway. Second, showing interest during visits in this topic, important to the patient, and conversing about it could help to establish a trusting relationship and therefore, according to our results, improving his or her quality of daily life, without using up very much of the physician’s time. That is, with the increasing transformation of cancer into a chronic disease comes the need for a different kind of relationship, one in which physicians can fulfill the relational needs of care. The issue here is not that oncologists should replace psychologists or psychiatrists [40], but rather that they have a relational tool that enables them to support the patient in their management of a serious and very trying chronic disease and thus to help them to maintain their quality of daily life. We chose to focus on patients’ daily life during their treatment period. This differs from, and is complementary with, others approaches such as shared decision making [41] or self-management [38], that also seek to improve patients’ quality of daily life and patient-physician relations.

Study limitations
Our qualitative study took place in three different centers and included patients with various types of cancer. These points make our findings transferable to other cancer contexts. However, some limitations must be taken into consideration. First, this took place in France, and caution is required in transposing our results to other places, especially non-Western countries, because cancer care depends strongly on the organization of the medical system as well as on the country’s economy. Second, our recruitment process did not allow us to include patients who have dropped out of treatment or those using complementary or alternative treatment, although they are relatively frequent in this clinical population [42]. This might have limited our findings. Third, all patients had undergone several treatments for at least 6 months and the median time since diagnosis in our sample was 4 years. Our results might not be relevant for patients who have just started treatment. Further qualitative studies should be made to address this specific period of time. Finally, our results don’t mention the influence of age on the quality of daily life. Further qualitative studies with specific age populations should be made to explore the extensive role age plays in this matter.

Conclusion
Quality of life is a daily concern for patients during cancer treatment. This qualitative study provides access to patients’ experience of their care and daily lives, allowing us to see cancer care through the patients’ eyes. In their daily clinical practice, doctors face multiple constraints — of time and workload — that hinder them from taking their patients’ subjective health status into account. We suggest as a start that they include in their practice a systematic interest for the support object that their patients have chosen.

Abbreviations
EBM: Evidence Based Medicine; PTSD: Post-traumatic stress disorder; QoL: Quality of life

Acknowledgements
We would like to thank all the patients for their participation in this study. We also want to thank Jo Ann Cahn for the translation in English.

Funding
The study was supported by Grant No. 00050334 from the Fondation de France, “Soigner, soulager, accompagner” 2014.

Availability of data and materials
The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
JS, LV, ARL conceived and designed the study; JS, CP, MO, ML collected the data; JS, CP, MO, ML, GB, LV, ARL analyzed the data; JS, LV, ARL wrote the paper. All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The Paris-Descartes University review board (CERES) approved the research protocol (IRB number: 2014060001072). All participants provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Service Universitaire de Psychiatrie de l’Adolescent, Argenteuil Hospital Centre, 69 rue du LTC Prud’hom, 95107 Argenteuil, France. 2ECSTRA Team, UMR-1153, Inserm, Paris Diderot University, Sorbonne Paris Cite, Paris, France. 3Department of Dermatology, Caen University Hospital, F-14033 Caen, France. 4Université de Caen Normandie, Medical School, F-14000 Caen, France. 5McGill Group for Suicide Studies, Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Canada.
References

1. Sorosnak R, Kulpa M, Ziętalewicz U, Wolski J, Nowakowski R, Bakula R, Demkow T. Basic issues concerning health-related quality of life. Cent Eur J Urol. 2017;70(2).

2. Bennett BM, Wells JR, Panter C, Yuan Y, Penrod JH. The Humanitarian Burden of Small Cell Lung Cancer (SCLC). A Systematic Review of Health-Related Quality of Life (HRQoL) Literature. Frontiers in Pharmacology. 2017;1,588.

3. Korol EE, Wang S, Johnston K, Ravandi-Kashani F, Levis M, van der Velden A. Health-related quality of life of patients with acute myeloid leukemia: a systematic literature review. Oncol Ther. 2017;3(1):1–16.

4. Walter T. Maintaining quality of life for patients with neuroendocrine tumours. Lancet Oncol. 2017;18(10):1299–300.

5. Ganguli A, Wiegand P, Gao X, Carter JA, Bottenman MF, Ray S. The impact of second-line agents on patients’ health-related quality of life in the treatment for non-small cell lung cancer: a systematic review. Qual Life Res. 2013;22(5):1015–26.

6. Mutsaers A, Greenspoon J, Walker-Dilks C, Swaminath A. Systematic review of primary and metastatic liver cancer. Radiat Oncol. 2017;12(1).

7. Siyam T, Ross S, Campbell S, Eurich DT, Yuksel N. The effect of hormone deprivation therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review. BMC Womens Health. 2017;17(1).

8. RETURN TO BREAST Collaborative group, D, et al. Patient reported quality of life following stereotactic ablative radiotherapy for primary and metastatic liver cancer. Radiat Oncol. 2017;12(1).

9. Siboni et al. BMC Cancer 2018;18:951

10. Gonzalez-saenz de Tejada M, Bilbao A, Baré M, Briones E, Sarasqueta C, Avicenne, Service d

11. Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, Buchwald C. Quality of life in survivors of oropharyngeal cancer: a systematic review and meta-analysis of 1366 patients. Eur J Cancer. 2017;78:291–104.

12. Shao Z, Zhu T, Zhang F, Wen Q, Li D, Wang S. Association of financial status and the quality of life in Chinese women with recurrent ovarian cancer. Health Qual Life Outcomes. 2017;15(1).

13. Chirico A, Lucidi F, Meruzzi T, Allerviemi F, Laurencis MD, Botti G, et al. A meta-analytic review of the relationship of cancer coping self-efficacy with distress and quality of life in colorectal cancer patients: social support, functional status, HRQoL, and distress in CRC. Psycho-Oncology. 2017;26(9):263–9.

14. Laughman S-A, Allenby A, Matthews J, Wirth A, Kissane D, Bishop M, et al. Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with Cancer. J Clin Oncol. 2001;19(21):4117–25.

15. Gonzalez-saenz de Tejada M, Bilbao A, Baré M, Briones E, Sarasqueta C

16. Mehnert A, Koch U. Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. Psycho-Oncology. 2007;1;16(3):181–188.

17. Zhen R, Quan J, Zhou X. Co-occurring patterns of post-traumatic stress disorder and depression among flood victims: a latent profile analysis. J Health Psychol. 2018;135910531876350.

18. Abbey G, Thompson SB, Hickish T, Heathcoe D. A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder. Psycho-Oncology 2015;1;14(4):371–381.

19. Lansen SE, Berenbaum H. Did the DS-4S improve the traumatic stressor criterion?: association of DSM-IV and DSM-5 criterion a with posttraumatic stress disorder symptoms. Psychopathology. 2017;50(6):373–8.

20. Kordost C, g. de Haes Je, Heisterkamp S, Bakker P, de Graeff A, de Haan R. Palliative chemotherapy or watchful waiting? A vignettes study among oncologists. JCO 2002;1;20(17):3658–3664.

21. Lerneux J, Mauriello E, Provencer L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology 2008;1;17(4):317–328.

22. Rosen AE, Case CE, Dusza SW, Balagula Y, Gordon J, West DP, et al. Impact of dermatologic adverse events on quality of life in 283 Cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol 2013;1;14(4):327–333.

23. Hershman D, Calhoun E, Zapert K, Wade S, Malin J, Barron R. Patients’ perceptions of physician-patient discussions and adverse events with Cancer therapy: patient perceptions of adverse events with chemotherapy. Arch Drug Inf. 2008;1;20(2):70–8.

24. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of Cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;10;26(23):3860–3866.

25. Song Y, Lv X, Liu J, Huang D, Hong J, Wang W, et al. Experience of nursing support from the perspective of patients with cancer in mainland China: nursing support for patients with cancer. Nurs Health Sci. 2016;18(4):510–8.

26. Wei C, Nengliang Y, Yan W, Qiong F, Yuan C. The patient-provider discordance issue? J Clin Oncol 2008 10;26(23):3860–3866.

27. Wei C, Nengliang Y, Yan W, Qiong F, Yuan C. The patient-provider discordance issue? J Clin Oncol 2008 10;26(23):3860–3866.

28. Best M, Butow P, Oliver I. Doctors discussing religion and spirituality: a systematic literature review. Palliat Med 2016;1;30(4):327–337.

29. Siboni et al. BMC Cancer 2018;18:951

30. Williams JA, Meltzer D, Arora V, Chung G, Curlin FA. Attention to inpatients’ religious and spiritual concerns: predictors and association with patient satisfaction. J Gen Intern Med. 2011;26(11):1265–71.

31. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of Cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;10;26(23):3860–3866.

32. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of Cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;10;26(23):3860–3866.

33. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of Cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;10;26(23):3860–3866.

34. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of Cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;10;26(23):3860–3866.

35. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of Cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;10;26(23):3860–3866.

36. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of Cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;10;26(23):3860–3866.

37. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of Cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;10;26(23):3860–3866.

38. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of Cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;10;26(23):3860–3866.

39. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of Cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 2008;10;26(23):3860–3866.